Opus Genetics IRD

Opus Genetics Inc is a clinical stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases and other ophthalmic disorders. The company was founded in February 2018 as Ocuphire Pharma Inc and has since undergone a series of mergers and acquisitions including a merger with Ocularis Pharma LLC in April 2018 the acquisition of certain rights to the Ref 1 inhibitor program from Apexian Pharmaceuticals Inc in January 2020 a reverse merger into Rexahn Pharmaceuticals Inc in November 2020 and the acquisition of a private corporation then operating under the name Opus Genetics Inc in October 2024. Its pipeline consists of seven adeno associated virus based gene therapy programs targeting LCA5 BEST1 RHO CNGB1 RDH12 NMNAT1 and MERTK as well as Phentolamine Ophthalmic Solution 0 point 75 percent a small molecule therapy approved by the FDA for pharmacologically induced mydriasis and being developed for presbyopia and low light vision disturbances after keratorefractive surgery and APX3330 a selective small molecule inhibitor of the Ref 1 protein for diabetic retinopathy. The LCA5 program OPGx LCA5 has received Rare Pediatric Disease Regenerative Medicine Advanced Therapy and Orphan Drug designations from the FDA and is being evaluated in a phase 1/2 clinical trial at the University of Pennsylvania with early data showing safety and signals of visual improvement. The BEST1 program OPGx BEST1 has received similar designations and dosed its first participant in a phase 1/2 trial in November 2025. The RHO RDH12 MERTK NMNAT1 and CNGB1 programs are in preclinical or IND enabling stages with support from foundations and government grants. The Phentolamine Ophthalmic Solution has completed pivotal phase 3 trials for presbyopia and low light indications and a supplemental new drug application has been submitted to the FDA with a PDUFA date set for October 2026. APX3330 has been studied in multiple phase 2 trials for diabetic retinopathy and the company is seeking a strategic partner to advance its phase 3 development.

Opus Genetics generates revenue primarily from licensing agreements milestone payments royalties and potential future product sales. The most significant agreement is the Viatris License Agreement signed in November 2022 under which the company granted Viatris an exclusive perpetual sublicensable license to develop manufacture import export and commercialize Phentolamine Ophthalmic Solution for reversal of mydriasis presbyopia and decreased vision under mesopic or low light conditions after keratorefractive surgery worldwide except for certain countries in Asia. In return Opus received an upfront nonrefundable cash payment of 35 million dollars and is eligible to receive additional milestone payments of up to 130 million dollars tied to regulatory or net sales achievements with the first 10 million dollar milestone already paid following FDA approval of the solution for mydriasis reversal in the third quarter of 2023. The company will also receive tiered royalties starting at low double digit percentages and rising to low 20 percent based on annual net sales of the licensed products in the United States and low double digit royalties on sales in the Viatris territory outside the United States. Additional license and collaboration agreements with the University of Pennsylvania Iveric and other institutions provide for milestone payments and royalty payments upon achievement of development regulatory and commercial milestones for the gene therapy programs. At present the company does not have any product sales revenue because its pipeline assets are largely in preclinical or early clinical stages and its income is derived mainly from upfront payments milestone receipts and royalty streams from partnered programs. The company has also received grant funding from entities such as the FDA Office of Orphan Drug Products the Foundation Fighting Blindness the National Institutes of Health and the Global RDH12 Alliance to support preclinical and clinical activities.

Opus Genetics competes in the highly competitive biopharmaceutical sector focusing on rare inherited retinal diseases and ophthalmic therapeutics. Its gene therapy programs face competition from established players such as Spark Therapeutics now part of Roche Novartis MeiraGTX and GenSight Biologics which are advancing AAV based treatments for various retinal disorders. For its Phentolamine Ophthalmic Solution the company competes with products such as AbbVie's VUITY Lenz Therapeutics LNZ100 and TenPoint Therapeutics YUVEZZI which are marketed for presbyopia and pharmacologically induced mydriasis. Opus Genetics differentiates itself through a diversified pipeline that targets multiple rare retinal genes with potentially first in class gene therapies for LCA5 and BEST1. The company has obtained several regulatory designations including Rare Pediatric Disease Regenerative Medicine Advanced Therapy Orphan Drug and Fast Track status for its lead programs and may be eligible for a Priority Review Voucher upon approval of a biologics license application. Its partnership with Viatris provides commercialization expertise and financial resources for the ophthalmic solution while its exclusive licenses from academic institutions and a strong intellectual property portfolio support the development of its gene therapy assets. The intellectual property estate includes numerous issued patents and pending applications covering compositions of matter therapeutic methods and formulations for its gene therapy programs and small molecule assets with expiration dates ranging from 2034 to 2046. The company also benefits from a clear regulatory path for rare diseases as evidenced by recent FDA interactions that acknowledged the significant unmet medical need for LCA5 and BEST1 patients and offered flexibility in trial design and review processes.

The company serves patients suffering from inherited retinal diseases such as LCA5 associated retinal degeneration BEST1 associated retinal disease various forms of retinitis pigmentosa and other ophthalmic conditions including presbyopia pharmacologically induced mydriasis and low light vision disturbances following keratorefractive surgery. Its products are intended for use by individuals diagnosed with these conditions and are typically prescribed by ophthalmologists and retinal specialists in the United States and in international markets. The end user base comprises patients and the physicians who treat them.